market seems to be more of a popularity contest until things eventuate. AYA just above cash value and heading into Q-Sub meeting with FDA. There is still some decent buying opportunities in the biotech market I think the gaps will close over the next 12-18 months so enjoy it whilst we can.
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark, page-50
Add COV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.020(5.41%) |
Mkt cap ! $28.56M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.5¢ | 35.0¢ | $69.91K | 194.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5655 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 15000 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| COV (ASX) Chart |